Gilead Sciences (GILD) and Merck (MRK) announced promising first data from a phase II study evaluating the combination of a once-weekly treatment regimen of Merck’s islatravir and Gilead’s lenacapavir.The data demonstrated the efficacy of this potential long-acting oral combination treatment option in maintaining viral suppression in individuals with HIV.At the 24-week mark, the combination of islatravir and lenacapavir showcased an impressive 94.2% rate of viral suppression (HIV-1 RNA <50 copies/mL), with ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from three studies evaluating the efficacy and safety profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) for a broad range of people with HIV, including those with HIV/hepatitis B (HBV) coinfection and HIV/tuberculosis (TB) coinfection. These data and other studies supporting the important role of Biktarvy in the HIV treatment landscape were presented at ...

FOSTER CITY, Calif., & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class capsid inhibitor. These late-breaking data were presented during an oral session at the 31st Conference on Retroviruses ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this HIV and hepatitis C drugmaker have returned -6.1% over the past month versus the Zacks S&P 500 composite's +2.9% change. The Zacks Medical - Biomedical and Genetics industry, to which Gilead belongs, has gained 1% over this period. Now the key question is: Where could the stock be ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from three real-world retrospective studies being presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI). One study showed Veklury® (remdesivir) was associated with a reduced risk of certain long-COVID symptoms in people who were hospitalized for COVID-19. In a separate study, Veklury use was associated with significantly reduced mortality among people who were immunocompromi ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of key data highlighting the breadth of its innovative HIV treatment research pipeline. The latest results explore clinical outcomes from a study evaluating an investigational combination regimen of bictegravir and lenacapavir, new findings from a study evaluating the investigational combination of lenacapavir with broadly neutralizing antibodies (bNAbs), and new proof-of-concept data on GS-1720, a no ...

Gilead Sciences, Inc. (NASDAQ:GILD) TD Cowen 44th Annual Health Care Conference March 5, 2024 12:50 PM ET Company Participants Andy Dickinson - Chief Financial Officer Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren Welcome, and good afternoon, everyone. Welcome again to TD Cowen's 44th Annual Healthcare Conference, Day 2. My name is Tyler Van Buren, senior biotech analyst here. For our next session, very pleased to have a fireside chat with Gilead. And from Gilead, it's my pleasure ...

Gilead Sciences, Inc. (NASDAQ:GILD) TD Cowen 44th Annual Health Care Conference March 5, 2024 12:50 PM ET Company Participants Andy Dickinson - Chief Financial Officer Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren Welcome, and good afternoon, everyone. Welcome again to TD Cowen's 44th Annual Healthcare Conference, Day 2. My name is Tyler Van Buren, senior biotech analyst here. For our next session, very pleased to have a fireside chat with Gilead. And from Gilead, it's my pleasure ...

The latest trading session saw Gilead Sciences (GILD) ending at $72.31, denoting a +0.29% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a gain of 0.8% for the day. Meanwhile, the Dow experienced a rise of 0.23%, and the technology-dominated Nasdaq saw an increase of 1.14%.The HIV and hepatitis C drugmaker's stock has dropped by 7.75% in the past month, falling short of the Medical sector's gain of 3.58% and the S&P 500's gain of 5.2%.Market participants will be ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $12.6 million in grant funding to 19 organizations working to improve the HIV landscape for Black women and girls in the United States. These grants are a part of Gilead’s new Setting the P.A.C.E. (Prevention, Arts and Advocacy, Community, Education) initiative, a three-year commitment toward increasing HIV prevention, anti-stigma and health equity efforts for Black cisgender and Transgender ...